People · Operator
Named in public records as an officer, director or promoter · active 2015–2024 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Intellia Therapeutics, Inc. | — | Biotechnology | Series C | $70.0M | $2.9B | 2015 |
| Focal Medical, Inc. | — | Biotechnology | Series A | $6.4M | $5.9M | 2024 |
| Korro Bio, Inc. | — | Biotechnology | Seed | $4.0M | $177.6M | 2019 |
Nessan Bermingham at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Nessan Bermingham on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Jean-Francois Formela | 2 | 17 |
| Carl Gordon | 1 | 24 |
| Joseph DeSimone | 1 | 5 |
| John Leonard | 1 | 4 |
| OMMER CHOHAN | 1 | 2 |
| Rachel Haurwitz | 1 | 2 |
| Michael Aldridge | 1 | 1 |
| Jen Jen S. Yeh | 1 | 1 |
| Anthony S. Voiers | 1 | 1 |
| Joseph S. DeSimone | 1 | 1 |
| Jose Rivera | 1 | 1 |
| Jen Jen Yeh | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.